Pomalyst Drug Side Effects Warnings

Pomalyst  Myeloma Drug Pomalyst Associated With Side Effects

 

 

 

 

 

 

Pomalyst (pomalidomide) is an immunomodulatory drug prescribed to treat multiple Myeloma (a type of cancer that affects white blood cells)

POMALYST SIDE EFFECTS

The side effects depend on the patient’s previous health history and their particular stage of myeloma. The most common serious side effects that have been observed are:

  • Low white blood cell counts
  • Pneumonia
  • Low red blood cell counts
  • Low platelets (thrombocytopenia)
  • Fatigue and weakness

MORE SERIOUS PRMALYST SIDE EFFECTS

Also in the May 2015 MHRA Drug Safety Update included these  Pomalyst side effects:

Cardiac failure

The study stated that heart failure was a common side effect [occurs in between 1/10 and 1/100 patients] who take the drug Pomalyst . In the majority of cases, this side effect occurred in patients with cardiac disease or cardiac risk factors and within six months of beginning treatment with Pomalyst . The MHRA Drug review also concluded that the drug Pomalyst can cause atrial fibrillation, which may trigger sudden heart failure.

Interstitial lung disease (ILD)

The ongoing study also indicated Pomalyst  can cause ILD as well as related undesirable effects such as pneumonitis. The study concluded that this side effect is common [occurs in between 1/10 and 1/100 patients who take Pomalyst (pomalidomide)]. The beginning of respiratory symptoms is typically within six months of starting treatment. Yet, there are cases where interstitial lung disease occurred 18 months after starting treatment with the drug Pomalyst.

Hepatotoxicity

It is well known that raises alanine aminotransferase and bilirubin levels. The study’s review found that  the drug Pomalyst  can also cause serious hepatotoxicity, primarily acute hepatitis.   Also reports of severe liver failure in patients receiving treatment with the drug Pomalyst; however it  could not be conclusively determine if Pomalyst  was the only  cause of liver failure in these particular cases. The concern for  serious hepatic events is the highest in the first 6 months of treatment.  Regular liver function monitoring is strongly  recommended during this period.

If you are taking Pomalyst (pomalidomide) for treatment of multiple Myeloma and have side effects or concerns, please contact our drug litigation lawyers  here or call (800) 486-4450 now.